Myeloperoxidase production by macrophage and risk of atherosclerosis

Current Atherosclerosis Reports

Volumn 14, Issue 3, 2012, Pages 277-283

  Karakas, Mahir ^a   Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Acute coronary syndrome; Atherogenesis; Cardiovascular disease; Myeloperoxidase

Indexed keywords

MYELOPEROXIDASE; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME SYNTHESIS; HUMAN; MACROPHAGE FUNCTION; PATHOPHYSIOLOGY; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ANIMALS; ATHEROSCLEROSIS; HUMANS; MACROPHAGES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIDASE; RISK FACTORS;

EID: 84861226590     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0242-3     Document Type: Article

References (49)

1. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-42. (Pubitemid 34041599)
2. Thomas EL, Learn DB, Jefferson MM,WeatherredW. Superoxidedependent oxidation of extracellular reducing agents by isolated neutrophils. J Biol Chem. 1988;263:2178-86. (Pubitemid 18060271)
3. Weiss SJ, Regiani S. Neutrophils degrade subendothelialmatrices in the presence of alpha-1-proteinase inhibitor. Cooperative use of lysosomal proteinases and oxygen metabolites. J Clin Invest. 1984;73:1297-303. (Pubitemid 14139524)
4. Jiang ZY, Woollard ACS, Wolff SP. Hydrogen peroxide production during experimental protein glycation. FEBS Lett. 1990;268:69-71. (Pubitemid 20233832)
5. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, SydowK, Lau D, Szöcs K,Klinke A, Kubala L, Berglund L, Schrepfer S, Deuse T, Haddad M, Risius T, Klemm H, Reichenspurner HC, Meinertz T, Heitzer T. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006;113:1871-8. (Pubitemid 43739399)
6. Leculier C, Couprie N, Adeleine P, Leitienne P, Francina A, Richard M. The effects of high molecular weight- and low molecular weightheparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes. Thromb Res. 1993;69:519-31. (Pubitemid 23106438)
7. Shih J, Datwyler SA, Hsu SC, Matias MS, Pacenti DP, Lueders C, Mueller C, Danne O, Möckel M. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem. 2008;54:1076-9. (Pubitemid 351793416)
8. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005;352:1685-95.
9. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45:993-1007. (Pubitemid 38679495)
10. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104:508-16.
11. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94:437-44. (Pubitemid 24218123)
12. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000;275:37524-32. (Pubitemid 32004861)
13. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, Freeman BA. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391-4. (Pubitemid 34734213)
14. Xu J, Xie Z, Reece R, Pimental D, Zou MH. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol. 2006;26:2688-95.
15. Carr AC,McCallMR, Frei B. Oxidation of LDL bymyeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol. 2000;20:1716-23. (Pubitemid 30470585)
16. Carr AC, Myzak MC, Stocker R, McCall MR, Frei B. Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS Lett. 2000;487:176-80. (Pubitemid 32057108)
17. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075-81. (Pubitemid 27203762)
18. Nicholls SJ, Zheng L, Hazen SL. Formation of dysfunctional highdensity lipoprotein by myeloperoxidase. Trends Cardiovasc Med. 2005;15:212-9. (Pubitemid 41338008)
19. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529-41. (Pubitemid 39572103)
20. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, Singh P, Anantharamaiah GM, Chait A, Brunzell J, Geary RL, Oram JF, Heinecke JW. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1- dependent cholesterol transport. Proc Natl Acad Sci U S A. 2004;101:13032-7. (Pubitemid 39167578)
21. Marsche G, Furtmuller PG, Obinger C, Sattler W, Malle E. Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro. Cardiovasc Res. 2008;79:187-94. (Pubitemid 351881925)
22. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, Didonato JA, Hazen SL. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13:1176-84. (Pubitemid 47530630)
23. Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res. 2009;50:S346-51. This review gives an excellent summary of the pathophysiologic effects of MPO in the development of atherosclerosis.
24. Kumar AP, Reynolds WF. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophy Res Commun. 2005;331:442-51. (Pubitemid 40602657)
25. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426-31. (Pubitemid 36935535)
26. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001;276:41279-87.
27. Shabani F, McNeil J, Tippett L. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCl) is suppressed by anti-rheumatic drugs. Free Radic Res. 1998;28:115-23. (Pubitemid 28288697)
28. Sugiyama S, Kugiyama K, Aikawa M, Makamura S, Ogawa H, Libby P. Hypochlorus acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol. 2004;24:1309-14. (Pubitemid 38880026)
29. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879-91. (Pubitemid 32221781)
30. Ferrante G, Nakano M, Prati F, Niccoli G, MallusMT, Ramazzotti V, Montone RA, Kolodgie FD, Virmani R, Crea F. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes. Circulation. 2010;122:2505-13. This study showed elevated MPO levels in patients with ACS syndrome presenting with eroded culprit plaque compared to patients presenting with ruptured culprit plaque, thereby supporting the concept that elevations in selective inflammatory biomarkers reflect specific acute complications of coronary atherosclerosis.
31. Biasucci LM, D'Onofrio G, Liuzzo G, Zini G, Monaco C, Caligiuri G, Tommasi M, Rebuzzi AG, Maseri A. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol. 1996;27:611-6. (Pubitemid 26080385)
32. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-604. (Pubitemid 37288567)
33. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW, CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440-5. (Pubitemid 37176448)
34. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schomig A, Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest. 2008;38:90-6. (Pubitemid 351143413)
35. PeacockWF, Nagurney J, Birkhahn R, Singer A, Shapiro N, Hollander J, Glynn T, Nowak R, Safdar B, Miller C, Peberdy M, Counselman F, Chandra A, Kosowsky J, Neuenschwander J, Schrock J, Plantholt S, Lewandrowski E,Wong V, Kupfer K, Diercks D. Myeloperoxidase in the diagnosis of acute coronary syndromes: the importance of spectrum. Am Heart J. 2011;162:893-9.
36. Apple FS, Smith SW, Pearce LA, Schulz KM, Ler R, Murakami MM. Myeloperoxidase improves risk stratification in patients with ischemia and normal cardiac troponin I concentrations. Clin Chem. 2011;57:603-8.
37. Scirica BM, Sabatine MS, Jarolim P, Murphy SA, de Lemos JL, Braunwald E, Morrow DA. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J. 2011;32:697-705. This large study on the prognostic role of MPO in CVD showed no incremental benefit for MPO in the context of highsensitivity troponin and NT-proBNP.
38. Duzguncinar O, Yavuz B, Hazirolan T, Deniz A, Tokgozoglu SL, Akata D, Demirpence E. Plasma myeloperoxidase is related to the severity of coronary artery disease. Acta Cardiol. 2008;63:147-52. (Pubitemid 351548698)
39. Karakas M, Koenig W, Zierer A, Herder C, Rottbauer W, Baumert J, Meisinger C, Thorand B. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. J Intern Med. 2012;271:43-50. This large study on the prognostic role of MPO in healthy adults demonstrated a moderate predictive value for incident CHD.
40. Heilman K, Zilmer M, Zilmer K, Lintrop M, Kampus P, Kals J, Tillmann V. Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with type 1 diabetes. Diabetes Res Clin Pract. 2009;84:168-73.
41. Ali C, Sarcia P, Mosley Jr TH, Kondragunta V, Kullo IJ. Association of serum myeloperoxidase with the ankle-brachial index and peripheral arterial disease. Vasc Med. 2009;14:215-20.
42. TangWH, KatzR, BrennanML, AvilesRJ, TracyRP, PsatyBM, Hazen SL. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure.AmJ Cardiol. 2009;103:1269-7.
43. Meuwese MJ, Stroes ESG, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals. J Am Coll Cardiol. 2007;50:159-65. (Pubitemid 47002189)
44. Rana JS, Arsenault BJ, Despres JP, Cote M, Talmud PJ, Ninio E, Jukema JW, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. Eur Heart J. 2009;32:336-44.
45. Wong ND, Gransar H, Narula J, Shaw L, Moon JH, Miranda-Peats R, Rozanski A, Hayes SW, Thomson LE, Friedman JD, Berman DS. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging. 2009;2:1093-9.
46. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, Masliah E. Myeloperoxidase polymorphism is associated with gender specific risk for alzheimer's disease. Exp Neurol. 1999;155:31-41. (Pubitemid 29072602)
47. Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF. Transgenic mice express human MPO -463 G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463 G males. J Lipid Res. 2006;47:1366-77. (Pubitemid 44079890)
48. Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferatoractivated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the 2463GA promoter polymorphism. J Biol Chem. 2004;279:8300-15. (Pubitemid 38294722)
49. Heslop CL, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol. 2010;55:1102-9.